7Baggers
Quarterly
Annual
    Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 
      
                             
      operating activities
                             
      net income
    -1,312,390 -1,267,218 -1,579,820 -1,987,401 -1,693,907 -1,867,917 -2,243,070 -1,803,221 -2,013,864 -2,233,380 -2,173,665 -1,672,362 -1,969,452 -2,290,643 -2,605,495 -2,267,862 -2,129,105 -6,967,395 -1,790,309 -1,418,228 -1,628,065 -2,114,096 -1,965,266 -1,760,632 -1,519,468 
      adjustments to reconcile net income to net cash from operating activities:
                             
      stock-based compensation expense
    131,587 126,578 254,029 281,639 281,758 280,140 284,572 354,972 355,752 366,924 381,061 454,200 463,995 399,411 561,348 476,867 478,574 362,955 310,162 318,855 331,303 344,841 378,959 378,203 380,062 
      non-cash interest expense
    126,027                         
      non-cash lease expense
       13,370 39,472 38,556 37,676 24,597                  
      change in operating assets and liabilities:
                             
      accounts receivable
    -19,515 -551,099 -778,833 560,833 -210,091 -336,511 -62,470 50,138 -309,327 53,267 -123,717 -73,027 -23,755 -70,616 -104,484           
      prepaid expenses and other current assets
    227,486 299,916 222,045                       
      inventories
    51,357 44,011 -106,936                       
      accounts payable and accrued expenses
    -188,084 242,624 343,596                     23,776 344,743 
      accrued compensation
    164,837 159,916 -1,058,129 494,341 216,737 212,681 -190,907 -125,836 188,328 116,467 -107,119 -291,473 189,314 192,682 -587,438           
      operating lease liabilities
       -13,370 -39,472 -38,556 -37,676 -24,597                  
      net cash from operating activities
    -818,695 -820,615 -2,579,390 -1,106,104 -1,041,605 -1,206,373 -1,630,895 -2,506,325 -1,100,925 -1,373,707 -1,615,030 -1,997,198 -5,892,138 -1,510,489 -2,953,119 -1,711,504 -1,810,528 -1,556,080 -1,551,895 -1,147,690 -1,059,090 -1,628,427 -1,926,886 -1,248,914 -1,149,938 
      financing activities
                             
      proceeds from february 2024 offering, net of issuance costs
    -1 6,718,212                       
      payment of february 2024 offering costs
    -426,293                       
      proceeds from march 2024 warrant amendment, net of issuance costs
                             
      proceeds from june 2024 warrant amendment, net of issuance costs
                             
      payment of august 2024 shelf registration statement offering costs
                             
      proceeds from september 2024 exercise price warrant amendment, net of issuance costs
                             
      proceeds from september 2024 warrant amendment, net of issuance costs
                             
      proceeds from exercise of pre-funded warrants
                             
      redemption of fractional shares due to reverse stock split
                             
      net cash from financing activities
    2,979,891 295,696 7,542,719     7,123,455 171,521 313,107 45,454 13,070,154 3,499,787 100,792 5,413,284 21,250 306,721 123,813 5,039,956 636,432 1,186,777 
      net increase in cash and cash equivalents
    2,161,196 -524,919 4,963,329     -2,506,325 -1,100,925 5,749,748 -1,443,509 -1,997,198 -5,579,031 -1,465,035 10,117,035 1,788,283 -1,709,736   -840,969 -935,277    36,839 
      cash and cash equivalents at beginning of period
    4,739,426 9,843,699 9,144,710 8,068,939 5,663,833 5,319,004 
      cash and cash equivalents at end of period
    2,161,196 -524,919 9,702,755 -1,225,400 -1,041,605 -1,206,373 8,212,804 -2,506,325 -1,100,925 5,749,748 7,701,201 -1,997,198 -5,579,031 -1,465,035 18,185,974 1,788,283 -1,709,736 3,857,204 4,133,188 -840,969 -935,277 3,411,529 4,028,550 -1,248,914 36,839 
      supplemental disclosure of non-cash financial activities
                             
      august 2024 shelf registration statement costs included in accounts payable and accrued expenses
                             
      september 2024 exercise price warrant amendment costs included in accounts payable and accrued expenses
                             
      september 2024 warrant amendment costs included in accounts payable and accrued expenses
                             
      raw materials
    -25,816 283,283                       
      finished goods
    -25,541 168,456 93,026                       
      total inventories
    -51,357 -44,011 588,776                       
      proceeds from amendment and exercise of series b warrants, net of issuance costs
     295,697 1,250,800                       
      warrant amendment costs included in accounts payable and accrued expenses
                             
      interest expense
      124,658                       
      supplemental disclosure of non-cash financing activities
                             
      offering costs included in accounts payable
      20,926                       
      work in process
      212,467                       
      prepaid expenses and other assets
                   -658,386 -193,579 228,042 227,089 229,299 -631,471 143,197 142,299 109,739 -355,275 
      inventory
                             
      accrued interest payable
                             
      proceeds from issuance of common stock from atm
             171,521              
      payment of atm offering costs
                             
      cash paid for offering costs
                             
      net cash (used)/provided by financing activities
                             
      net (decrease)/ increase in cash and cash equivalents
                             
      non-cash financing activities
                             
      public offering costs included in accounts payable and accrued expenses
                             
      operating lease right-of-use asset obtained in exchange for operating lease liabilities
                             
      common stock options
       -15,369 -6,000 76,250 569,351 -4,921,615 5,413,466 -136,874 -377,374 135,448 5,392,259 -195,806 -13,306 297,000 3,989,371 -118,500 -439,753 3,672,624 
      total excluded securities
       -15,369 -6,000 76,250 569,351 -4,933,615 5,425,466 -136,874 -539,580 135,448 7,234,138 -188,280 -547,267 -60,719 6,727,646 17,706 -111,206 -445,879 6,392,311 26,879 -130,612 
      prepaid expenses, inventory and other assets
        255,737 151,193 206,079  343,521 318,355 227,100  352,046 344,250 359,617           
      accounts payable and other accrued expenses
                             
      accrued interest expense
        126,028 124,657 123,288 126,027 126,028 124,657 123,288 125,065 126,028 125,619 122,589           
      payment of common stock offering costs from atm
                             
      net (decrease)/increase in cash and cash equivalents
                             
      supplemental disclosure of non-cash investing and financing activities
                             
      operating lease right-of-use assets obtained in exchange for operating lease liabilities
                             
      accounts payable and other current liabilities
         229,384 251,613 -86,378 208,637 -119,997 58,022 307,773 -30,314 -201,192 -604,126  -19,860 -179,682 -298,837  869,143 -2,369 -482,878   
      net decrease in cash and cash equivalents
         -1,206,373 -1,630,895            -1,530,645    -1,290,454   
      warrants to purchase common stock
              12,000 -162,206 1,841,879 -478,598 -393,084 2,713,561 2,713,561 -84,000 
      reserve for obsolete inventory
                             
      forgiveness of paycheck protection loan and accrued interest
               -962 -104,168           
      milestone payable
                            
      proceeds from issuance of common stock
                  -21,250 3,309,116 21,250 306,721 123,813 5,039,956 636,432 1,186,777 
      payment of common stock offering costs
                             
      proceeds from issuance of common stock from exercise of stock options
                            
      deferred rent expense
                  9,038           
      proceeds from issuance of common stock from employee stock purchase plan
                            
      proceeds from issuance of common stock from stock options exercises
                             
      proceeds from paycheck protection program
                           
      proceeds from eversana line of credit
                   3,000,000         
      employee stock purchase plan
                   7,526 -55,363 35,365 24,714 17,706   6,126 8,088 -16,447 
      proceeds from issuance of common stock, net of cost of 1,304,846
                  13,070,154           
      accounts payable and accrued liabilities
                             
      milestone expense
                            
      accrued interest
                             
      proceeds from issuance of common stock from stock option exercised
                             
      change in fair value of warrant liability
                           
      reclassification of warrant liability to equity due to amendment of warrants
                           
      common stock subject to repurchase
                             
      reclassification of warrant liability to equity due to exercise of warrants
                             
      non-cash interest
                             
      financing costs allocated to warrant liability
                             
      payment on bank loan
                             
      proceeds from issuance of common stock and warrants
                             
      supplemental disclosure of cash flow information
                             
      interest paid
                             
      fair value of warrants issued to placement agent
                             
      deferred financing costs paid in prior year
                             
      proceeds from bank line of credit
                             
      payment on bank line of credit
                             
      costs paid in connection with loan origination
                             
      cash paid for interest
                             
      non-cash financing activities deferred financing costs paid in prior year
                             
      other assets
                             
      issuance of series a convertible preferred stock warrants
                             
      conversion of series a convertible preferred stock to common stock at the initial public offering
                             
      change in fair value of purchase right liability
                             
      proceeds from convertible promissory note
                             
      proceeds from bank line of credit and loan advances
                             
      proceeds from issuance of preferred stock and purchase rights
                             
      proceeds from exercise of stock options
                             
      supplemental disclosures of cash flow information
                             
      conversion of convertible promissory note and accrued interest to series a convertible preferred stock
                             
      gross proceeds
                             
      underwriting discounts and commissions and non-accountable expense allowance
                             
      total offering costs
                             
      net proceeds
                             
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.